KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Accumulated Depreciation & Amortization (2016 - 2025)

Teva Pharmaceutical Industries (TEVA) has disclosed Accumulated Depreciation & Amortization for 17 consecutive years, with $4.7 billion as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization rose 7.19% to $4.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.7 billion through Dec 2025, up 7.19% year-over-year, with the annual reading at $4.7 billion for FY2025, 7.19% up from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $4.7 billion at Teva Pharmaceutical Industries, up from $4.4 billion in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $5.6 billion in Q4 2023, with the low at $4.4 billion in Q4 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $5.1 billion, with a median of $5.2 billion recorded in 2021.
  • The sharpest move saw Accumulated Depreciation & Amortization fell 21.77% in 2024, then rose 7.19% in 2025.
  • Teva Pharmaceutical Industries' Accumulated Depreciation & Amortization stood at $5.2 billion in 2021, then increased by 5.29% to $5.5 billion in 2022, then rose by 2.16% to $5.6 billion in 2023, then dropped by 21.77% to $4.4 billion in 2024, then rose by 7.19% to $4.7 billion in 2025.
  • Per Business Quant, the three most recent readings for TEVA's Accumulated Depreciation & Amortization are $4.7 billion (Q4 2025), $4.4 billion (Q4 2024), and $5.6 billion (Q4 2023).